University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Aug;397(8):6153-6163. doi: 10.1007/s00210-024-03007-9. Epub 2024 Mar 2.
Depression is a debilitating mood disorder affecting millions worldwide and continues to pose a significant global health burden. Due to the multifaceted nature of depression, the current treatment regimens are not up to mark in terms of their multitargeting potential and least side effect profile. Molecules within the isoflavone class demonstrate promising potential in alleviating depression and associated conditions, offering a multifaceted approach to manage mental health concerns. Therefore, the current study was designed to explore the potential of glycitein, an isoflavone in managing reserpine-induced depression and associated comorbidities in mice. Reserpine (0.5 mg/kg; i.p.) administration for the first 3 days induced depression and associated comorbidities as evidenced by increased immobility time in forced swim test (FST) and tail suspension test (TST), along with reduced locomotor activity in the open field test (OFT) and increased latency to reach the platform in the Morris water maze (MWM) test. Reserpine treatment also upregulated and downregulated the brain thiobarbituric acid reactive substance (TBARS) and glutathione (GSH) levels, respectively. Furthermore, reserpine administration also uplifted the level of TNF-α in the serum samples. Glycitein (3 mg/kg and 6 mg/kg; p.o.) treatment for 5 days prevented the depressive effect of reserpine. It also improved the spatial memory at both dose levels. Moreover, in biochemical analysis, glycitein also reduced the brain TBARS and serum tumor necrosis factor-alpha (TNF-α) levels. Whereas, no significant effect was seen on the brain GSH level. Glycitein (6 mg/kg) was found to be more effective than the 3 mg/kg dose of glycitein. Overall results delineate that glycitein has the potential to manage depression and impaired memory by inhibiting lipid peroxidation and inflammatory stress.
抑郁症是一种影响全球数百万人的衰弱性情绪障碍，继续对全球健康造成重大负担。由于抑郁症的多面性质，目前的治疗方案在其多靶点潜力和最小副作用特征方面并不理想。异黄酮类中的分子在缓解抑郁症和相关疾病方面显示出有希望的潜力，为管理心理健康问题提供了一种多方面的方法。因此，本研究旨在探索黄豆苷元（一种异黄酮）在管理利血平诱导的抑郁和相关合并症方面的潜力。利血平（0.5mg/kg；ip）连续 3 天给药可诱导抑郁和相关合并症，如强迫游泳试验（FST）和悬尾试验（TST）中的不动时间增加，旷场试验（OFT）中的运动活性降低，以及 Morris 水迷宫（MWM）试验中到达平台的潜伏期增加。利血平处理还分别上调和下调了大脑硫代巴比妥酸反应物质（TBARS）和谷胱甘肽（GSH）水平。此外，利血平给药还提高了血清样本中 TNF-α的水平。黄豆苷元（3mg/kg 和 6mg/kg；po）连续 5 天给药可预防利血平的抑郁作用。它还改善了两个剂量水平的空间记忆。此外，在生化分析中，黄豆苷元还降低了大脑 TBARS 和血清肿瘤坏死因子-α（TNF-α）水平。然而，大脑 GSH 水平没有显著变化。黄豆苷元（6mg/kg）比 3mg/kg 剂量的黄豆苷元更有效。总体结果表明，黄豆苷元通过抑制脂质过氧化和炎症应激具有治疗抑郁和记忆障碍的潜力。
